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Aberrant activation of the transcription factor NF-κB, as well as uncontrolled inﬂammation, has been linked to autoimmune
diseases, development and progression of cancer, and neurological disorders like Alzheimer’s disease. Reporter cell lines are a
valuable state-of-the art tool for comparative analysis of in vitro drug screening. However, a reporter cell line for the
investigation of NF-κB-driven neuroinﬂammation has not been available. Thus, we developed a stable neural NF-κB-reporter
cell line to assess the potency of proinﬂammatory molecules and peptides, as well as anti-inﬂammatory pharmaceuticals. We
used lentivirus to transduce the glioma cell line U251-MG with a tandem NF-κB reporter construct containing GFP and ﬁreﬂy
luciferase allowing an assessment of NF-κB activity via ﬂuorescence microscopy, ﬂow cytometry, and luminometry. We
observed a robust activation of NF-κB after exposure of the reporter cell line to tumour necrosis factor alpha (TNFα) and
amyloid-β peptide [1-42] as well as to LPS derived from Salmonella minnesota and Escherichia coli. Finally, we demonstrate that
the U251-NF-κB-GFP-Luc reporter cells can be used for assessing the anti-inﬂammatory potential of pharmaceutical
compounds using Bay11-7082 and IMD0354. In summary, our newly generated cell line is a robust and cost-eﬃcient tool to
study pro- and anti-inﬂammatory potential of drugs and biologics in neural cells.
1. Introduction
The inducible transcription factor nuclear-factor “kappa-
light-chain-enhancer” of activated B-cells (NF-κB) is a key
regulator of inﬂammation [1]. The NF-κB protein family
consists of the DNA-binding subunits p65 (RelA), RelB, c-
Rel, p50, and p52 [2, 3], which bind to consensus elements
on DNA (κB-elements/binding sites with the sequence 5′
GGGACTTTCC3′). In its inactive form, NF-κB hetero- or
homodimers reside in the cytoplasm bound to the inhibitory
IκB protein which prevents nuclear translocation of the com-
plex. Upon activation of the signalling cascade, the inhibitor
of NF-κB (IκB) kinase (IKK) complex consisting of IKKα,
IKKβ, and NF-κB essential modulator (NEMO) is activated.
IKK complex in turn phosphorylates inhibitory IκB proteins,
for example, IκBα, IκBβ, or IκBε [4–6]. This phosphorylation
at serine residues (e.g., serine 32 and 36 for IκBα) promotes
polyubiquitination and proteasomal degradation of IκBs
[7]. The liberated NF-κB dimers translocate into the nucleus
and bind to their consensus elements and modulate the tran-
scription of target genes [7]. This canonical NF-κB signalling
cascade can be activated by pathogen-associated molecular
patterns (PAMPs) or damage-associated molecular patterns
(DAMPs) (mediated by Toll-like receptor 4 (TLR4)), proin-
ﬂammatory cytokines, and other external stimuli including
UV-irradiation [8, 9].
Chronic inﬂammation and ongoing activation of NF-κB
is linked to a variety of diseases including inﬂammatory
bowel disease [10], chronic obstructive pulmonary disease
(COPD) [11], and neuropathologies like Alzheimer’s disease
[12] and epilepsy [13]. In addition, it has been shown that
NF-κB is involved in the development and progression of
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cancer [14]. In this regard, NF-κB directly regulates cancer
cell proliferation by upregulation of G1 cyclins, particularly
cyclin D1 [15, 16]. Moreover, NF-κB positively modulates
expression levels of several chemokines (e.g., MCP-1) [17],
proangiogenic factors, for example, vascular endothelial
growth factor (VEGF) [18], and cellular inhibitors of
apoptosis [19].
The human cell line U251-MG was isolated from a 75-
year-old male Caucasian patient by explant technique from
brain tissue of a grade III-IV malignant astrocytoma tumour
at the Wallenberg laboratory in Uppsala (Sweden) in 1973
[20–22]. Nonclonal U251-MG cells are highly heterogeneous
and contain diﬀerentiated cells and cancer stem cell-like cells
[23]. The U251 cell line represents an ideal tool to study
inﬂammatory signalling pathways. Indeed, this cell line has
been used previously to study inﬂammatory responses
in vitro [24–27]. In contrast to many standard cell lines, for
example, HEK 293 which do not express TLRs, U251 cells
are characterised by the expression of TLRs (except TLR2)
[26], TNF receptor 1 (TNFR) [28], and interleukin receptors
[27]. Thus, these cells are suitable for studying proinﬂamma-
tory signals, particularly those proposed as endogenous
TLR4 ligands, without overexpression artefacts.
In this study, we describe the development and character-
isation of a U251-derived cell line stably transduced with a
lentiviral NF-κB-driven tandem reporter encoding for GFP
and luciferase. We validated the cell line using established
proinﬂammatory molecules including TNFα and bacterial
lipopolysaccharides (LPS). Using this U251-NF-κB-GFP-
Luc cell line, the NF-κB activating properties of proposed
endogenous TLR4-ligands (amyloid-β peptide [1-42] or
high mobility group box 1 (HMGB1) and LPS chemo-
types) were evaluated. Moreover, by using our reporter cell
line, the anti-inﬂammatory potential and in vitro toxicity
of anti-inﬂammatory drugs and biopharmaceuticals can
be investigated.
2. Materials and Methods
2.1. Cell Culture. All cell lines were cultivated in normal cul-
tivation medium (Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) High Glucose (Sigma-Aldrich Company Ltd.,
Dorset, UK), 1% L-glutamine (200mM, Sigma-Aldrich),
10% heat-inactivated fetal calf serum (FCS, lot:126K3398,
Sigma-Aldrich)) in the absence of antibiotics and antimyco-
tics in a humidiﬁed incubator (Thermo Fisher Scientiﬁc,
Loughborough, UK) at 37°C and 5% CO2 unless stated other-
wise. Cells were provided with fresh medium every 2-3 days
and passaged at 90% conﬂuency.
2.2. Lentiviral Transduction. HEK293-FT cells were culti-
vated with normal cultivation medium containing polyethy-
lenimine (PEI, 0.1%). Medium was discarded after 16 h, and
cells were incubated in normal cultivation medium contain-
ing 25μM chloroquine. Transfection was performed using
2M CaCl2, TE-buﬀer, and 2x HBS supplemented with lenti-
viral package plasmids (6μg pCMV-VSV.G and 15μg
pCMV-dR8.91) and 20μg pGreenFire-NF-κB-Puro (System
Biosciences, Palo Alto, CA, USA) vectors. After 16h,
medium was discarded and the virus particles were harvested
after 24 h in normal cultivation medium. The virus con-
taining medium was centrifuged at 1985g for 10min and
ﬁltered through a 0.45μm ﬁlter (VWR International Ltd.,
Lutterworth, UK), prior to centrifugation (20000g, 2 h
15min, 4°C). The supernatant was discarded, and the virus
particles were resuspended in DMEM containing 1% L-
glutamine and stored at 4°C. For lentiviral transduction
of U251 cells, the medium was replaced with the pre-
warmed virus particle solution mixed with 10% FCS and
incubated for 8 h at 37°C and 5% CO2 before normal cul-
tivation medium was added. After 2 passages, cells were
selected using 5μg/ml puromycin (Apollo Scientiﬁc, Bred-
bury, UK). After 2 weeks, 12 single clones were generated
using limited dilution under normal culture conditions.
Finally, 4 clones were analysed in activity assays. The
clone showing the highest dynamics of luciferase activity
in response to TNFα was used for all experiments.
2.3. Stimulation of Cells. For TNFα stimulation, cells were
(unless otherwise indicated) treated with 10 ng/ml human
recombinant TNFα (PeproTech EC Ltd., London, UK, in
0.1% BSA (cell culture grade, Sigma-Aldrich) in PBS
(Sigma-Aldrich)) for 24h. For immunocytochemical
staining, cells were treated with TNFα for 15min prior to ﬁx-
ation. All cells treated with TLR4 ligands (peptides and LPS)
or NF-κB inhibitors were serum starved for 4 h before stimu-
lation for 48 h with normal cultivation medium comprising
respective ligands: 1μg/ml (unless stated otherwise) ultra-
pure LPS derived from Salmonella minnesota (ultrapure S.
minnesota R595 in endotoxin-free water, InvivoGen, Tou-
louse, France) or Escherichia coli (ultrapure E. coli LPS in
endotoxin-free water, InvivoGen); 0.1–100μg/ml ﬁbrinogen
from human plasma (50–70%, Sigma-Aldrich, dissolved in
DMEM High Glucose and sterile ﬁltered); 50–1000 ng/ml
high mobility group box 1 (human recombinant, carrier-
free HMGB1, BioLegend Ltd., London, UK, dissolved in
0.1% BSA in PBS); 0.001–10μM amyloid-β peptide [1-42]
(Aβ, rPeptide, Suﬀolk, UK, prepared in DMEM High Glu-
cose) or heated Aβ (stock solution boiled at 90°C for
45min); and 0.5–2.5μM Bay11-7082 (Sigma-Aldrich, in
DMSO (cell culture grade, Apollo Scientiﬁc)) or IMD0354
(10mM, Sigma-Aldrich, in DMSO).
2.4. Immunocytochemistry. U251 cells were seeded on cell
culture-treated coverslips in 12-well plates (Sarstedt,
Leicester, UK) and treated with TNFα as described above.
After 20min ﬁxation in 4% paraformaldehyde (Sigma-
Aldrich), cells were permeabilised using PBS containing
0.02% Triton X-100 (Sigma-Aldrich) and 5% normal goat
serum (Stratech Scientiﬁc Unit, Suﬀolk, UK) for 30min. Cells
were incubated with mouse anti-human p65 primary anti-
body (1 : 100 in PBS, sc8008, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) for 1.5 h at room temperature.
Cells were exposed to secondary goat anti-mouse IgG con-
jugated to AlexaFluor555 (1 : 300 in PBS, Life Technologies
Ltd., Paisley, UK) for 1 h at room temperature in the dark.
Nuclear counterstaining was achieved using DAPI (1 : 2000
in PBS, Sigma-Aldrich).
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2.5. Microscopy. Fluorescence microscopy of ﬁxed samples
was performed using AxioImager Epiﬂuorence System (Carl
Zeiss, Jena, Germany). Images of living cells (GFP and bright
ﬁeld images) were obtained using Nikon NIS Camera
(Nikon, Surrey, UK) equipped with an A1 Inverted Epiﬂuor-
ence Microscope (Zeiss).
Image acquisitionwas performedusingmicroscope-based
analysis software (Axiovision4), and Fiji was used for pixel
intensity measurement and further image processing [29].
2.6. Transfection of HEK293-MD2-CD14 and U251 cells.
U251 cells (Cell Line Service, Eppelheim, Germany) or
HEK293-MD2-CD14 cells (InvivoGen) were transfected
with pRL-CMV (Promega Corporation, Southampton,
UK), TK (NF-κB6) LUC [30], TLR4-GFP (InvivoGen), or
EGFP (after removal of endotoxins according to Ma
et al. [31]) using Turbofect® Tranfection Reagent (Thermo
Fisher Scientiﬁc). Transfection was assessed by expression
of GFP using epiﬂuorescence microscopy (A1 Inverted
Epiﬂuorescence Microscope, Carl Zeiss).
2.7. Luciferase Measurement. NF-κB-dependent ﬁreﬂy
luciferase activity and NF-κB-independent Renilla luciferase
activity were assessed using Dual-Luciferase® Reporter Assay
System (Promega Corporation). Luciferase activity of U251-
NF-κB-GFP-Luc cells was analysed using ﬁreﬂy luciferase
assay system (Promega Corporation), and all luciferase mea-
surements were performed using a Lucy 1 microplate reader
(Anthos Labtec, Salzburg, Austria).
2.8. Flow Cytometry. U251-NF-κB-GFP-Luc cells were culti-
vated and treated for 24h with TNFα or vehicle as described
above. After Trypsin-EDTA (Sigma-Aldrich) treatment and
centrifugation (300g, 10min), cells were resuspended in
PBS. GFP ﬂuorescence intensity (105 events per sample)
was measured using BD Accuri™ C6 plus ﬂow cytometer
(BD Biosciences, USA). Data were analysed using FlowJo
(FlowJo LLC, Ashland, USA).
2.9. MTT Assay. U251-NF-κB-GFP-Luc cells were serum-
deprived for 4 h and exposed to LPS derived from E. coli
and S. minnesota (10−2, 10−1, 1, 101, and 102μg/ml) or left
untreated for 68h. MTT assays (Promega Corporation) were
performed according to the manufacturer’s guidelines, and
readout was carried out using Lucy 1 microplate reader
(Anthos Labtec).
2.10. Statistical Analysis. All statistical analyses were per-
formed using GraphPad Prism software (GraphPad, La
Jolla, CA, USA). Data were compared using either Student’s
t-test (two-tailed, conﬁdence interval 95%) or one-way
analysis of variance (ANOVA) with Bonferroni correction
(CI 95%), where appropriate. At least 3 independent mea-
surements were performed, and p < 0 05 was considered
statistically signiﬁcant. Luciferase and MTT data are pre-
sented as mean± SEM, and pixel intensity measurements
are presented as mean± SD.
3. Results
3.1. The Inﬂammatory Response in U251 Cells Is
Heterogeneous. To assess TNFα-driven nuclear translocation
of NF-κB in U251 cells, p65 subunit localization was assessed
by immunoﬂuorescence, followed by acquisition of its ﬂuo-
rescence intensity in the nucleus (Figures 1(a) and 1(b)).
Treatment with TNFα resulted in signiﬁcantly increased
nuclear p65 ﬂuorescence compared to unstimulated cells
(Figure 1(a) lower panel, Figure 1(b)). Notably, the TNFα-
induced nuclear translocation in the nonclonal U251 popula-
tion is heterogeneous with a highly responsive subpopulation
(Figure 1(a), arrowheads), cells with intermediate levels of
nuclear p65, and cells without nuclear translocation
(Figure 1(a), asterisk).
Similarly, subpopulation of cells spontaneously translo-
cating p65 into the nucleus was identiﬁed in nonstimu-
lated cells (control, Figure 1(b)). In parallel experiments,
U251 cells were cotransfected with a NF-κB-dependent
luciferase reporter and a constitutively active Renilla lucif-
erase construct (transfection control) (Figure 1(c)). Signif-
icantly increased NF-κB-dependent luciferase activity was
observed after 24 h exposure to TNFα compared to the
control (Figure 1(c)).
3.2. U251-NF-κB-GFP-Luc Cell Line Combines Visual
Readout and Quantiﬁcation of NF-κB Activation. In order
to combine both a visual and quantiﬁable readout without
the inﬂuence of population heterogeneity, we lentivirally
transduced U251 cells using the pGreenFire-NF-κB-Puro
plasmid (Figure 1(d)). When stimulated with diﬀerent con-
centrations of TNFα, clone A1 (U251-NF-κB-GFP-Luc-A1)
revealed the highest levels of luciferase luminescence and
thus it was used in further experiments (Figure 2(a)).
Next, U251-NF-κB-GFP-Luc-A1 cells were exposed to
TNFα, followed by an assessment of GFP ﬂuorescence using
ﬂuorescence microscopy and ﬂow cytometry (Figures 2(b)
and 2(c)). No GFP ﬂuorescence was detected in control U251
cells, whereas low basal signal was observed in unstimulated
U251-NF-κB-GFP-Luc-A1 cells (Figure 2(b)). Notably, TNFα
treatment signiﬁcantly increased the levels of GFP in U251-
NF-κB-GFP-Luc-A1 cells compared to untreated reporter cells.
3.3. Biased Agonism Is Detectable in U251-NF-κB-GFP-Luc
Cells. In a recent study, we reported that LPS chemotypes
with diﬀerent acetylation patterns mediate diﬀerential
levels of NF-κB activation in U251 cells [26]. To test if
the newly developed cell line has suﬃcient sensitivity to
detect broad ranges of LPS concentrations and ligand-
dependent activation of NF-κB, we applied various con-
centrations of LPS derived from either S. minnesota or E.
coli and analysed the NF-κB-dependent luciferase biolumi-
nescence. In accordance with our previous ﬁndings
obtained in untransduced U251 cells [26], we were able
to detect concentration-dependent changes in NF-κB acti-
vation for both LPS chemotypes (Figure 2(d)). In addition,
the assay was also able to detect ligand-dependent diﬀer-
ences in NF-κB activation (E. coli versus S. minnesota
LPS) (Figure 2(d)). Next, we investigated the viability of
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U251-NF-κB-GFP-Luc cells using MTT assays. Cells were
exposed to variable concentrations of E. coli or S. minne-
sota LPS, and viability was assessed after 3 days. We
observed signiﬁcantly decreased viability of the cells when
treated with 100μg/ml S. minnesota LPS after 3 days com-
pared to nontreated cells (Figure 2(e)). In contrast, con-
centration of E. coli LPS had no eﬀect on the viability of
U251-NF-κB-GFP-Luc cells (Figure 2(f)).
3.4. U251-NF-κB-GFP-Luc Cells Can Be Used in Screening for
Endogenous TLR4-Ligands.NF-κB is an important readout in
TLR4 signalling, and we demonstrated that this reporter cell
line can be used to distinguish between ligand-dependent
and concentration-dependent eﬀects of TLR4 ligands
(Figure 2(d)). Therefore, we investigated NF-κB activation in
response to the potential endogenous TLR4 ligands ﬁbrino-
gen, HMGB1, and amyloid-β.
No activation of NF-κB was observed when U251-NF-κB-
GFP-Luc cells were treated with ﬁbrinogen (Figure 3(a)). Next,
we examined NF-κB-driven luciferase activity after exposure
of the reporter cells to HMGB1. A signiﬁcantly decreased
luciferase activity was measured when cells were stimulated
with 50ng/ml HMGB1, compared to unstimulated controls
(Figure 3(b)). At higher concentrations, no eﬀect of HMGB1
treatment was detectable; however, a signiﬁcant increase was
observed in cells treated with the respective amount of vehicle
alone (0.1% BSA in PBS) (Figure 3(c)).
To further investigate the eﬀect of HMGB1, we used
a TLR-deﬁcient cell background. HEK293 cells stably
expressing the TLR4 coreceptors MD2 and CD14 were
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Figure 1: U251 cells respond heterogeneously to a proinﬂammatory trigger. (a) Immunocytochemistry of the NF-κB subunit p65 (magenta)
shows nuclear translocation of NF-κB after stimulation with TNFα for 15min (arrowheads). Note the heterogeneous response in p65 nuclear
translocation in U251 cells (asterisk). Scale bar: 100 μm. (b) Quantiﬁcation of nuclear p65 intensity showed signiﬁcant increase of nuclear
translocated NF-κB in TNFα-treated U251 cells compared to untreated U251-cells. Data are presented as mean± SD from three diﬀerent
measurements (merged), compared using Student’s t-test (unpaired, two-tailed, CI 95%). ∗∗∗p < 0 001. (c) Increased relative luciferase
activity was observed in U251 cells transiently transfected with a NF-κB-dependent luciferase reporter. Mean± SEM from three diﬀerent
experiments are shown, analysed using unpaired Student’s t-test (two-tailed, CI 95%). ∗∗∗p < 0 001. (d) Schematic display of the lentiviral
NF-κB-dependent luciferase reporter. NF-κB activation leads to binding of NF-κB to respective response elements, enhancing GFP and
luciferase reporter gene expression through activation of the minimal CMV promoter.
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transfected with a transient NF-κB-dependent luciferase
reporter construct, a Renilla luciferase transfection control,
andTLR4-GFPorGFP, respectively.Thus, itwas expected that
TLR4 ligands would promote an increase in luciferase activity
inTLR4-GFP cells but not in cells expressingGFP alone.Here,
50 ng/ml HMGB1 also led to decreased NF-κB-dependent
luciferase expression in TLR4-deﬁcient cells (Figure 3(d)).
Amyloid-β [1-42] peptide promotes TLR4-mediated
activation of NF-κB, often in association with TLR2 [32].
To investigate if amyloid-β [1-42] can activate NF-κB in
the absence of TLR2, we exposed U251-NF-κB-GFP-Luc
cells to increasing concentrations of amyloid-β. Amyloid-β
signiﬁcantly increased NF-κB-dependent luciferase activity
(Figure 3(e)). HEK293-MD2-CD14 cells were transfected
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Figure 2: GFP and luciferase expression is increased inU251-NFκB-GFP-Luc cells after activation of NF-κB signalling. (a) Stimulation with 10ng/
ml TNFα for 24 h signiﬁcantly increases NF-κB-dependent luciferase activity in U251-NF-κB-GFP-Luc cells. Mean± SEM from three independent
experiments are shown, compared using Student’s t-test (unpaired, two-tailed, CI 95%). ∗∗p < 0 01. (b) Fluorescence microscopy and (c) ﬂow
cytometry was applied to visualize the increase of GFP expression in U251-NF-κB-GFP-Luc cells after 24 h stimulation with 10ng/ml TNFα.
Scale bar: 100μm. (d) U251-NF-κB-GFP-Luc cells were triggered for 24 h with diﬀerent concentrations of LPS derived from E. coli (LPSE. coli,
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A signiﬁcantly higher luciferase activity was shown using E. coli LPS compared to S. minnesota LPS. (e) U251-NF-κB-GFP-Luc cells were
treated with diﬀerent concentrations of S. minnesota LPS or (f) E. coli LPS for 3 days before analysis using an MTT assay. Note that 100μg/ml
S. minnesota LPS signiﬁcantly decreased cell viability. The presented values are mean± SEM from three diﬀerent experiments, analysed using
ANOVA with Bonferroni correction (∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 was considered signiﬁcant, CI 95%) to compare between
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Figure 3: Proposed endogenous TLR4-ligands can be tested using U251-NF-κB-GFP-Luc cells (a). No changes in NF-κB-dependent
luciferase activity were observed using 0.1, 1, 10, or 100μg/ml ﬁbrinogen. (b) 50 ng/ml high mobility group box 1 (HMGB1) led to a slight
decrease whereas vehicle (0.1% cell culture grade BSA in PBS) induced an increase in luciferase activity in U251-NF-κB-GFP-Luc cells. (c)
Evaluation of TLR4-dependence in response to HMGB1 using HEK293-MD2-CD14 cells transfected with a transient NF-κB-luciferase
reporter and GFP or TLR4-GFP. 50μM HMGB1 led to a signiﬁcant decrease in cells transfected with GFP only. E. coli LPS: positive
control. Control: nontreated. (d) 5 and 10μM, but not 0.1 and 1 μM amyloid-β-peptide [1-42], signiﬁcantly increased NF-κB-dependent
luciferase in the U251 reporter cells. (e) HEK293-MD2-CD14 were cotransfected with a transient NF-κB-luciferase reporter and GFP or
TLR4-GFP. 5μM amyloid-β-peptide [1-42], but not heated amyloid-β (control for LPS contamination), signiﬁcantly increased luciferase
activity. E. coli LPS: positive control. Control: nontreated. Data are presented as mean± SEM from at least 3 independent experiments.
∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 were considered signiﬁcant, ANOVA with Bonferroni correction, CI 95%.
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with respective luciferase reporters and either TLR4-GFP
or only GFP. Stimulation with 5μM amyloid-β or 1μg/
ml E. coli LPS did not result in NF-κB activation in the
absence of TLR4. However, in the presence of TLR4,
amyloid-β signiﬁcantly increased luciferase activity,
comparable to E. coli LPS (Figure 3(f)). The amyloid-β
peptide used here was an E. coli-derived recombinant
protein, and thus LPS contamination could not be
excluded. As LPS is not heat sensitive [33], we heat-
inactivated the amyloid-β peptide (hAβ) for 45min at
90°C, which has been reported to denaturate occurring
oligomers and interfere with biological activity [34]. The
relative NF-κB-dependent luciferase activity in the hAβ
was signiﬁcantly lower compared to the native amyloid-β
peptide and not signiﬁcantly diﬀerent from the untreated
control (Figure 3(f)).
3.5. U251-NF-κB-GFP-Luc Cells Can Be Used as a Screening
System for Anti-Inﬂammatory Compounds. To evaluate
whether the moderate basal NF-κB activity of U251-NF-κB-
GFP-Luc cells is helpful in detection of anti-inﬂammatory
molecules or drugs, we ﬁrst tested a range of concentrations
of Bay11-7082, a general IKK inhibitor (poorly selective for
IKK1 or IKK2) proposed as a potential compound for glioma
treatment [35] without an additional proinﬂammatory
trigger. We detected a signiﬁcant decrease of basal NF-κB
activity at concentrations higher than 1.5μM compared to
DMSO-treated (vehicle) cells (Figure 4(a)).
In addition, the function of the IKKβ is essential for
NF-κB-activation, as it phosphorylates the cytosolic inhibi-
tor of NF-κB, IκB. Moreover, IKKβ is part of NF-κB activa-
tion in the MyD88-dependent signalling pathway triggered
by E. coli LPS. We therefore examined IMD0354, an IKKβ
inhibitor, in the absence and presence of E. coli LPS. 1μM
and 10μM IMD0354 signiﬁcantly decreased the NF-κB-
dependent luciferase activity in U251-NF-κB-GFP-Luc cells.
When simultaneously stimulated with E. coli LPS, 0.1μM
IMD0354 slightly reduced NF-κB activity; however, 1μM
and 10μM IMD0354 resulted in signiﬁcant reduction of
LPS-mediated activation of NF-κB (Figure 4(b)). In sum,
the basal NF-κB activity of U251-NF-κB-GFP-Luc cells is
very valuable in detection of anti-inﬂammatory drugs.
4. Discussion
NF-κB plays a pivotal role in the development and homeosta-
sis of the immune system, epithelium, and skeletal system
(reviewed in [36]) as well as the central nervous system
(reviewed in [37]). Due to this central physiological role, its
dysregulation is associated with a range of pathological
conditions, including autoinﬂammatory neurodegenerative
disorders and cancer.
In this study, we describe a new NF-κB reporter cell line,
suitable as a screening system to investigate pro- and anti-
inﬂammatory biologicals and pharmaceutical compounds.
Several NF-κB reporter cells have been generated to date.
The most common cells used for the generation of NF-κB
reporter cell lines are HEK293 cells stably transfected with a
NF-κB luciferase reporter (System Biosciences (NF-κB/293/
GFP-Luc™) or SEAP (secreted embryonic alkaline phospha-
tase, Invivogen (HEK-Blue™ Null cells)). However, a com-
mon drawback of HEK293-based reporter cells is the
absence of endogenously expressed TLRs. Therefore, these
receptorsmust be (stably or transiently) overexpressed result-
ing in potential overexpression artefacts (reviewed in [38]).
Other available NF-κB reporter cell lines include a
colon carcinoma cell line (HCT116, Invivogen) and lung
carcinoma cell line (A549, Invivogen). Both of these are
dual reporter cell lines, generated for the simultaneous
investigation of the activation of interferon regulatory fac-
tor (IRF3/7) [39] and NF-κB. These reporter systems are
very valuable when studying TLR4-mediated signalling.
However, these cells are not particularly useful when
studying neuroinﬂammation.
The macrophage THP-1-NF-κB-Lucia cell line (Invivo-
gen) can also be used for investigation of proinﬂammatory
signalling mediated by TLR4. Importantly, immunomodula-
tion and macrophage polarization (M1, M2) can be studied
using these cells. However, THP-1-NF-κB-Lucia cells require
a nonstandard luciferase substrate (for Lucia luciferase) and
additional chemicals for cultivation (zeocin, normocin).
Until now, no NF-κB reporter cell line has been
generated from a glioblastoma cell line. Constitutively active
NF-κB is associated with invasive behaviour, increased pro-
liferation, and inﬂammation of various cancers including
glioblastoma [40]. In accordance to that, we observed a basal
NF-κB-driven GFP expression in U251-NF-κB-GFP-Luc
cells (Figures 1, 2(a), 2(b), and 2(c)), indicating constitutively
active NF-κB. When triggered with the proinﬂammatory
cytokine, TNFα, both luciferase expression and GFP ﬂuores-
cence intensity were increased (Figures 2(b) and 2(c)). The
advantage of our cell line compared to others mentioned pre-
viously is that NF-κB activity can be monitored at both pop-
ulation (luciferase) and single cell (GFP) level.
Previously, we have demonstrated that the response of
U251 cells after exposure to bacterial LPS depends on the
chemotype of the LPS [26]. TLR4-mediated signalling can
lead to two diﬀerent signalling pathways, dependent on the
intracellular adapter protein. The MyD88-dependent path-
way leads to an early NF-κB activation, whereas the
MyD88-independent pathway leads to activation of inter-
feron regulatory factor 3 (IRF3), and also to a later activation
of NF-κB. As NF-κB is the common denominator in signal-
ling mediated by TLR4, we investigated if biased signalling
can be examined using U251-NF-κB-GFP-Luc cells. We suc-
cessfully demonstrated that our newly generated reporter cell
line is suitable to investigate biased TLR4 signalling, in this
case in response to E. coli or S. minnesota LPS (Figure 2(d)).
Although pathogen-associated inﬂammation has been
intensely studied, sterile (nonseptic) inﬂammation due to
endogenous molecules is not completely understood and
even debated. Several studies suggest an involvement of TLRs
in the occurrence of nonseptic inﬂammation. In this regard,
most endogenous ligands studied until now seem to activate
NF-κB signalling via TLR4 [41], particularly ﬁbrinogen [42]
and HMGB1 [43, 44]. U251 cells endogenously express pro-
teins involved in the TLR4 signalling pathway and do not
need to be transfected [25, 26]. In U251-NF-κB-GFP-Luc
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cells, ﬁbrinogen had no eﬀect on NF-κB-activation whereas
HMGB1 seemed to decrease the activity of NF-κB. The eﬀect
of HMGB1 was further veriﬁed using the commonly used
HEK293-MD2-CD14 cells. Here, HMGB1 decreased the
luciferase activity in both cells transfected with respective
luciferase reporters and GFP and TLR4-GFP, showing that
HMGB1 might not be a speciﬁc ligand for TLR4. Although
we observed a slight increase in NF-κB-dependent luciferase
activity with increasing HMGB1 concentrations in our
reporter cells (Figure 3(b)), it is very likely that this response
was due to the vehicle used as recommended by the manufac-
turer (0.1% BSA in PBS). Notably, we were able to detect an
increase in luciferase activity when U251-NF-κB-GFP-Luc
cells were stimulated with increasing amounts of 0.1% BSA
in the cultivation medium (Figure 3(b)).
Recently, TLR4 and TLR2 have been shown to play a
signiﬁcant role in neuroinﬂammation occurring during
Alzheimer’s disease [12, 32]. By stimulating TLR2-deﬁcient
U251-NF-κB-GFP-Luc cells and TLR4-transfected HEK293-
MD2-CD14 cells with the amyloid-β peptide [1-42], we
conﬁrmed that amyloid-β signals through TLR4, leading to
NF-κB activation in our NF-κB reporter cells (Figure 3(c)).
Tsan and Gao [45] recently proposed that positive responses
after exposure to endogenous protein ligands are due to LPS
contaminations of the peptide solutions. They demonstrated
that heat inactivation can be used to detect LPS contami-
nations in recombinant proteins produced in E. coli [45].
Heat-inactivated amyloid beta peptide did not promote a
NF-κB-dependent response in our reporter cell line, indi-
cating that our observations are not due to contaminations
with endotoxins (Figure 3(e)).
We also tested if our reporter cells can be used as a phar-
macological tool to identify anti-inﬂammatory compounds
(Figure 4). In the present study, we also showed that our cell
line can be used to investigate NF-κB inhibitors, as shown as
using previously characterised inhibitors of the NF-κB sig-
nalling pathway, Bay11-7082, and IMD0354. Bay11-7082
has already been applied to U251 cells by Wang et al. to
demonstrate the importance of NF-κB in the resistance to
chemotherapy [46]. In our study, both inhibitors signiﬁ-
cantly reduced NF-κB-dependent luciferase activity indepen-
dently of the presence of LPS, pointing out the beneﬁts of the
basal NF-κB activity when inhibitors are applied (Figure 4).
Notably, stably transduced cells are known to undergo geno-
typic changes with increasing cultivation time even in the
presence of selection antibiotics. Consequently, a prolonged
cultivation of the U251-NF-κB-GFP-Luc cells may result in
a phenotypic shift and a potentially reduced responsiveness
over time. In our hands, U251-NF-κB-GFP-Luc cells were
phenotypically stable for up to 10 passages. However, we rec-
ommend to prepare an adequate number of frozen stocks at
early passages.
5. Conclusions
In this study, we described the generation and characterisa-
tion of a stable NF-κB reporter cell line allowing the assess-
ment of NF-κB activity based on the expression of GFP and
luciferase activity. As aberrant regulation of NF-κB activation
is associated with several diseases, for example, cancer,
pharmacological tools for identiﬁcation and cytotoxicity
of NF-κB-inhibiting molecules are of medical interest. Our
reporter cell line can be used for investigation of proinﬂam-
matory molecules and peptides. Moreover, cytotoxicity and
mode of action of anti-inﬂammatory pharmaceuticals can
be investigated.
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Figure 4: U251-NF-κB-GFP-Luc cells are suitable for testing the anti-inﬂammatory potential of drugs (a). The NF-κB-inhibitor Bay11-7082
signiﬁcantly reduced NF-κB-dependent luciferase activity at concentrations higher than 1.5 μM. Vehicle: DMSO. (b) The IKKβ inhibitor
IMD0354 diminished NF-κB-dependent luciferase activity at various concentrations (0.1, 1, and 10μM) both in the presence or absence of
1μg/ml E. coli LPS. Data are presented as mean± SEM from at least 3 independent experiments. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001
were considered signiﬁcant, ANOVA with Bonferroni correction, CI 95%.
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